|
|
 |
|
Viewing report
|
|
|
|
Anti-hypertensives: Patent Defense Strategies - Combating Generic Competition Through Lifecycle Management
Datamonitor, Jan 2001
It is evident that patents provide an incentive for pharmaceutical companies to invest in research and development (R&D), since they enable companies to recoup the money spent during the development and launch of a new product. However, once patents expire, generic competition tends to result in a dramatic decline in the sales of the branded product and, therefore, companies are developing increasingly sophisticated strategies for defending and competing against generic competition. This brief will focus on the effect of patent expiries, both past and future, on the anti-hypertensives market since this is the largest pharmaceutical market in terms of value and constitutes a crucial component of the portfolio of the leading cardiovascular companies. However, although the brief concentrates on the anti-hypertensives market, which is already highly genericized and currently facing another major round of patent expiries, many of the principles outlined can be applied to other markets.
Customers who bought this item also bought
Br Malls Participacoes Sa
Br. Holdings Corporation
Market Dynamics 2001: Anti-hypertensives - Aiirbs battle for supremacy
Strategic Perspectives 2001: Portfolio Management in the Anti-Fungal Market
The World Market for Butadiene Rubber (BR): A 2009 Global Trade Perspective
The 2009 Import and Export Market for Butadiene Rubber (BR) in Belarus
The 2009 Import and Export Market for Butadiene Rubber (BR) in Bulgaria
The 2009 Import and Export Market for Butadiene Rubber (BR) in Uruguay
The 2009 Import and Export Market for Butadiene Rubber (BR) in Iran
The 2009 Import and Export Market for Butadiene Rubber (BR) in Colombia
The 2009 Import and Export Market for Butadiene Rubber (BR) in Estonia
The 2009 Import and Export Market for Butadiene Rubber (BR) in Slovakia
|
|
|
|
